Home › GLP-1 Medications › Eli Lilly › Mounjaro
Latest four-week snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.
GLP-1 Medications · 1 wave · n=72 answers, pooled
How often each assistant brings the brand up in recommendation answers.
| assistant | share of voice | answers |
|---|---|---|
| ChatGPT | 83% | 20 of 24 |
| Claude | 96% | 23 of 24 |
| Gemini | 58% | 14 of 24 |
Wave-by-wave share of recommendation answers that named this brand.
| wave | share of voice | answers | change |
|---|---|---|---|
| 2026-08-05 | 79% | 57 of 72 |
Recurring descriptions in the assistants' own words, grouped by theme.
“Mounjaro is a first-in-class dual GIP and GLP-1 receptor agonist.”
“If you **do not** have Type 2 diabetes, insurance will almost certainly deny coverage for Mounjaro. You will have to pay the full out-of-pocket retail price (often upwards of $1,000/month).”
“If you do not have Type 2 diabetes and your goal is chronic weight management, **Zepbound** is the correct choice.”
“They are administered as a weekly injection, have the same side effects, and come in the exact same doses (ranging from 2.”
“Rybelsus is a daily oral tablet, whereas Mounjaro is a once-weekly subcutaneous injection.”
“* **Your primary goals are maximum weight loss and superior blood sugar control:** Mounjaro is a dual-action medication (targeting both GIP and GLP-1 receptors), making it highly effective.”
“If your insurance covers them, or if you qualify for the manufacturers' copay savings cards, you could pay as little as **$25 per month**.”
“If you need a GLP-1 receptor agonist to control your blood sugar but dread the idea of weekly injections (like standard Ozempic, Trulicity, or Mounjaro), Rybelsus is highly effective.”
“(Zepbound is not approved for diabetes; its sister drug, Mounjaro, is).”
“**Short answer:** for many people with **type 2 diabetes**, Mounjaro (tirzepatide) is worth considering—especially if you also want substantial weight loss and have not met your A1C goals with other treatment.”
204 exact quoted mentions in this snapshot, grouped by coded tone.
“tirzepatide (Mounjaro/Zepbound) tends to show greater average weight loss in trials than semaglutide”
“tirzepatide-based drugs (Mounjaro/Zepbound) have shown greater average weight loss in trials than semaglutide-based ones”
“Technically a dual GIP/GLP-1 agonist; often shows the strongest results for both blood sugar and weight”
“**Tirzepatide** (Mounjaro) – often shows strong effects on blood sugar and weight, injectable, once weekly”
“These undergo formal FDA review for safety and efficacy, so their approved labeling and core efficacy claims are backed by clinical trial data.”
“**Mounjaro** (tirzepatide)”
“**Mounjaro** – approved for type 2 diabetes, sometimes used off-label for weight loss”
“**Tirzepatide** – sold as Mounjaro (diabetes) and Zepbound (weight loss); a dual GLP-1/GIP agonist”
“or **Mounjaro** (diabetes)”
“**FDA-approved drug ads (Ozempic, Wegovy, Zepbound, Mounjaro)**: Regulated, but still repeatedly flagged for overselling benefits or downplaying risks”
“**Do not choose Ozempic or Mounjaro solely because they are popular.** They contain the same active ingredients as Wegovy and Zepbound, respectively, but are branded and FDA-approved primarily for type 2 diabetes”
“Do **not** simply substitute Ozempic/Mounjaro for Wegovy/Zepbound on your own.”
“Avoid compounded "semaglutide" or "tirzepatide," research peptides, and products claiming to be generic Ozempic/Wegovy/Mounjaro/Zepbound.”
“Do not buy Ozempic or Mounjaro "for weight loss" on your own; they are branded for diabetes, while **Wegovy and Zepbound** are the FDA-approved brands specifically for chronic weight management.”
“Avoid choosing Ozempic or Mounjaro solely because they seem cheaper for weight loss: insurers commonly restrict them to their diabetes indications”
Which competitors assistants suggest when shoppers ask for something cheaper.
30 of 204 mentions appear alongside an identifiable web citation. Citation does not establish causation.
| cited source | mentions |
|---|---|
| noom.com | 4 |
| goodrx.com | 4 |
| injectco.com | 3 |
| pandameds.com | 3 |
| peptidedeck.com | 2 |
| formblends.com | 2 |
| preventionclinics.com | 2 |
| doctronic.ai | 2 |
| glpchart.com | 1 |
| cochrane.org | 1 |
| everydayhealth.com | 1 |
| fda.gov | 1 |
Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.